Cite
HARVARD Citation
Lee, C. et al. (n.d.). 76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma. Annals of oncology. p. . [Online].